Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs
nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy
(SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it
will stimulate the body's immune system to work against tumor cells. This study will test an
investigational use of nivolumab.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute